<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373552</url>
  </required_header>
  <id_info>
    <org_study_id>FattoumaBourguiba</org_study_id>
    <nct_id>NCT03373552</nct_id>
  </id_info>
  <brief_title>Genetic Polymorphism Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease</brief_title>
  <official_title>Determination of Genetic Polymorphisms Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Fattouma Bourguiba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel non-responsiveness is probably multifactorial; several genetic and non genetic
      factors may contribute to impaired platelet inhibition by clopidogrel. In this regard, it is
      meaningful to determine genetic polymorphisms contributing to the variability of clopidogrel
      response in patients with Coronary Artery Disease (CAD). In fact, the recognition of these
      factors might predict the exposure to the risk of thrombosis and cardiovascular death in
      these patients. Therefore, the goal of this study is to determine the impact of the
      polymorphisms, affecting CYP2C19, ABCB1, PON1 and P2RY12 genes, on the response to
      clopidogrel in patients with CAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an observational study with cross-sectional analysis and prospective data collection, the
      investigators recruit patients with:

        -  &gt;20 years old

        -  An established coronary artery disease defined by an episode of ST‐elevation myocardial
           infarction, non‐ST‐elevation acute coronary syndrome or stable angina

        -  An exposure to clopidogrel therapy (75 mg per day for at least 7 consecutive days).

      The exclusion criteria are:

        -  Presence of allergy to clopidogrel

        -  Severe hepatic dysfunction, disease or active pathological bleeding (e.g.,
           gastrointestinal (GI) bleeding)

        -  Use of glycoprotein IIb/IIIa inhibitors or cilostazol

        -  inability to give informed consent.

      Collected data for patients encompasse baseline characteristics, including age, gender,
      obesity (defined as a body mass index ≥30 kg/m2), smoking, medical history, and
      coadministered drugs.

      The study protocol was approved by the Ethics Committee for Clinical Research at our center
      and all subjects gave informed consent for study participation.

      Platelet function assay is assessed by the VerifyNow P2Y12 analyzer following manufacturer
      instructions (Accumetrics, Inc. San Diego, CA, USA) using venous blood samples collected in
      tube containing 3.2% sodium citrate.

      Genotyping for CYP2C19, ABCB1, PON1 and P2RY12 polymorphism is performed using the polymerase
      chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Platelet reactivity on clopidogrel</measure>
    <time_frame>at least after 7 days</time_frame>
    <description>Platelet reactivity on clopidogrel is assessed by the VerifyNow P2Y12 assay</description>
  </primary_outcome>
  <other_outcome>
    <measure>Genotyping for genetic polymorphisms</measure>
    <time_frame>an average of 1 month</time_frame>
    <description>Genotyping for genetic polymorphisms is performed using PCR-RFLP and sequencing</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Clopidogrel</condition>
  <arm_group>
    <arm_group_label>non responder Group</arm_group_label>
    <description>Platelet function assay:
High platelet reactivity: PRU&gt;230</description>
  </arm_group>
  <arm_group>
    <arm_group_label>responder Group</arm_group_label>
    <description>Platelet function assay:
PRU&lt;230</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Platelet function assay</intervention_name>
    <description>Platelet function assay</description>
    <arm_group_label>non responder Group</arm_group_label>
    <arm_group_label>responder Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease treated by clopidogrel therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;20 years old

          -  Established coronary artery disease defined by an episode of ST‐elevation myocardial
             infarction, non‐ST‐elevation acute coronary syndrome or stable angina

          -  Exposure to clopidogrel therapy (75 mg per day for at least 7 consecutive days).

        Exclusion Criteria:

          -  Presence of allergy to clopidogrel

          -  Severe hepatic dysfunction

          -  Disease or active pathological bleeding (e.g., gastrointestinal (GI) bleeding)

          -  Use of glycoprotein IIb/IIIa inhibitors or cilostazol

          -  inability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chouchene saoussen, assistant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fattouma Bourguiba Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saoussen chouchene, assistant</last_name>
    <phone>216 97772361</phone>
    <email>saoussen_chouchene@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fattouma Bourguiba Hospital</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>saoussen Chouchene, assistant</last_name>
      <phone>216 97772361</phone>
      <email>saoussen_chouchene@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>saoussen chouchene, assistant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Universitaire Fattouma Bourguiba</investigator_affiliation>
    <investigator_full_name>Chouchene Saoussen</investigator_full_name>
    <investigator_title>Professor Assistant in hematology</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease; Clopidogrel; Polymorphism, genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

